ADDLIFE AS AN INVESTMENT
AddLife creates value
Four reasons to own shares in AddLife
AddLife creates value through a strong corporate culture, a decentralised business model and active ownership that gives our employees and subsidiaries significant responsibility and good opportunities for development. Through independent, entrepreneur‑driven companies close to customers, combined with support, knowledge and tools from our large Group, we drive profitable growth over time. Strategic acquisitions strengthen our market positions, broaden our offering and add new talent, which together make AddLife an attractive long‑term investment in the Life Science market.
1. Attractive non-cyclical growth market
AddLife predicts that the medtech market has an average annual growth rate of 5 percent and the diagnostics market 2–3 percent. Many of the niches that AddLife has prioritised are growing even faster. The market is relatively insensitive to cyclical fluctuations and is driven by demographic factors, an ageing population and the increasing prevalence of chronic diseases. The demographic factors, together with technological development, an increased demand for preventive and personalised medicine and an increased focus on time-saving processes, are increasing the demand for AddLife’s products in healthcare, Homecare, diagnostics and research.
- Medtech CAGR: 5 percent
- Diagnostics CAGR: 2-3 percent
2. Cash flow finances growth
In recent years, the Company’s ambition has been to reduce net debt supported by its own cash flow. In 2025, AddLife has achieved and exceeded this ambition and can therefore going forward allocate the majority of its cash flow to organic and acquisition-driven growth. The Company’s acquisition agenda is based on financing acquisitions through its own cash flows. AddLife strives for profitable organic growth and has a high proportion of recurring sales and long-term contracts that generate stable cash flows. With a focus on working capital and profitability, the Company thereby generates strong and stable cash flows over time that can finance growth.
Operating cash flow:
- +27 percent growth
- Net debt reduced ~900 SEKm
3. Clear strategy to create growth
A key element of AddLife's growth strategy is acquisitions, with a focus on small and mid-sized bolt-on acquisitions or standalone acquisitions with attractive margins. The company has extensive experience in acquisitions, with an established process for identifying target companies and executing successful transactions. The goal is for the acquired subsidiaries to continue to develop based on their strengths, with the foundation of a decentralised business model, and with the support of an active owner with extensive experience of the Life Science market. Company-specific targets are set for the independent subsidiaries, which are linked to the Group's financial targets.
- Target 15 percent EBITA growth per year
- Average 29 percent since 2019
4. Strong market position in Europe
AddLife’s business model is based on AddLife, through its subsidiaries, creating value and building leading market positions in selected market niches in Europe. The Group has a broad geographical presence with operations in 30 countries, where AddLife’s subsidiaries have well-established sales organisations with high technical expertise which, in combination with the differentiated product and service portfolio, create strong long-term customer relationships and the conditions for good business.
- 30 countries
- 85 subsidiaries
- 2 300 employees